Summary
Celcuity Inc (Celcuity) is a clinical-stage biotechnology company specializing in developing targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor for the treatment of breast cancer, prostate cancer and gynecological cancer. Celcuity is also developing VIKTORIA-1, VIKTORIA-2 and CELC-G-201 therapeutics. The company utilizes the CELsignia platform, to identify abnormal oncogenic signaling pathways in cancer patients. It partners with pharmaceutical companies to evaluate targeted therapies' efficacy in cancer patients. Celcuity is headquartered in Minneapolis, Minnesota, the US.This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Celcuity Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Celcuity Inc Company Overview
- Celcuity Inc Company Snapshot
- Celcuity Inc Pipeline Products and Ongoing Clinical Trials Overview
- Celcuity Inc - Pipeline Analysis Overview
- Celcuity Inc - Key Facts
- Celcuity Inc - Major Products and Services
- Celcuity Inc Pipeline Products by Development Stage
- Celcuity Inc Pipeline Products Overview
- CELsignia CDx Test - Early Breast Cancer
- CELsignia CDx Test - Early Breast Cancer Product Overview
- CELsignia CDx Test - Herceptin + Perjita + Chemo
- CELsignia CDx Test - Herceptin + Perjita + Chemo Product Overview
- CELsignia CDx Test - Ibrance + Fulvestrant
- CELsignia CDx Test - Ibrance + Fulvestrant Product Overview
- CELsignia CDx Test - Metastatic Breast Cancer
- CELsignia CDx Test - Metastatic Breast Cancer Product Overview
- CELsignia CDx Test - Nerlynx + Tabrecta
- CELsignia CDx Test - Nerlynx + Tabrecta Product Overview
- CELsignia Test - Bladder Cancer
- CELsignia Test - Bladder Cancer Product Overview
- CELsignia Test - Colon Cancer
- CELsignia Test - Colon Cancer Product Overview
- CELsignia Test - Kidney Cancer
- CELsignia Test - Kidney Cancer Product Overview
- CELsignia Test - Lung Cancer
- CELsignia Test - Lung Cancer Product Overview
- CELsignia Test - Ovarian Cancer
- CELsignia Test - Ovarian Cancer Product Overview
- CELx HSF Test
- CELx HSF Test Product Overview
- CELx Test - Hematological Cancer
- CELx Test - Hematological Cancer Product Overview
- Celcuity Inc - Key Competitors
- Celcuity Inc - Key Employees
- Celcuity Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- Celcuity Inc, Recent Developments
- Aug 04, 2022: Celcuity Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
- Jan 19, 2021: Celcuity to Present at the B. Riley Oncology Investor Conference
- Jul 01, 2020: Celcuity hosting call on CELsignia Pathway Activity Test for ovarian cancer
- Jun 22, 2020: Celcuity presents data at AACR Annual Meeting for CELsignia Pathway Activity Test for Ovarian Cancer
- Dec 11, 2019: Celcuity presents results at the 2019 San Antonio Breast Cancer Symposium evaluating a sub-group of PIK3CA WT breast cancer patients who have hyperactive signaling tumors responsive to PI3K inhibitors
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Celcuity Inc Pipeline Products and Ongoing Clinical Trials Overview
- Celcuity Inc Pipeline Products by Equipment Type
- Celcuity Inc Pipeline Products by Indication
- Celcuity Inc, Key Facts
- Celcuity Inc, Major Products and Services
- Celcuity Inc Number of Pipeline Products by Development Stage
- Celcuity Inc Pipeline Products Summary by Development Stage
- CELsignia CDx Test - Early Breast Cancer - Product Status
- CELsignia CDx Test - Early Breast Cancer - Product Description
- CELsignia CDx Test - Herceptin + Perjita + Chemo - Product Status
- CELsignia CDx Test - Herceptin + Perjita + Chemo - Product Description
- CELsignia CDx Test - Ibrance + Fulvestrant - Product Status
- CELsignia CDx Test - Ibrance + Fulvestrant - Product Description
- CELsignia CDx Test - Metastatic Breast Cancer - Product Status
- CELsignia CDx Test - Metastatic Breast Cancer - Product Description
- CELsignia CDx Test - Nerlynx + Tabrecta - Product Status
- CELsignia CDx Test - Nerlynx + Tabrecta - Product Description
- CELsignia Test - Bladder Cancer - Product Status
- CELsignia Test - Bladder Cancer - Product Description
- CELsignia Test - Colon Cancer - Product Status
- CELsignia Test - Colon Cancer - Product Description
- CELsignia Test - Kidney Cancer - Product Status
- CELsignia Test - Kidney Cancer - Product Description
- CELsignia Test - Lung Cancer - Product Status
- CELsignia Test - Lung Cancer - Product Description
- CELsignia Test - Ovarian Cancer - Product Status
- CELsignia Test - Ovarian Cancer - Product Description
- CELx HSF Test - Product Status
- CELx HSF Test - Product Description
- CELx Test - Hematological Cancer - Product Status
- CELx Test - Hematological Cancer - Product Description
- Celcuity Inc, Key Employees
- Glossary
- Celcuity Inc Pipeline Products by Equipment Type
- Celcuity Inc Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Crinetics Pharmaceuticals Inc
- Sage Therapeutics Inc
- Alnylam Pharmaceuticals Inc
- Kura Oncology Inc
- Vertex Pharmaceuticals Inc
